Search

Your search keyword '"White, Darrell"' showing total 5 results
Start Over Author "White, Darrell" Journal european journal of haematology
5 results on '"White, Darrell"'

1. Outcome of carfilzomib/pomalidomide‐based regimens after daratumumab‐based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis

Author

LeBlanc, Richard, primary, Mian, Hira, additional, Reece, Donna, additional, Su, Jiandong, additional, Masih‐Khan, Esther, additional, Chu, Michael, additional, Jimenez‐Zepeda, Victor, additional, Sebag, Michael, additional, Song, Kevin, additional, Louzada, Martha, additional, Kotb, Rami, additional, Visram, Alissa, additional, White, Darrell, additional, Stakiw, Julie, additional, Reiman, Antony, additional, Aslam, Muhammad, additional, Bergstrom, Debra, additional, Kaedbey, Rayan, additional, Gul, Engin, additional, and Venner, Christopher, additional

Published
2023
Full Text
View/download PDF

2. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics

Author

Richardson, Paul G., primary, Schjesvold, Fredrik, additional, Weisel, Katja, additional, Moreau, Philippe, additional, Anderson, Larry D., additional, White, Darrell, additional, Rodriguez‐Otero, Paula, additional, Sonneveld, Pieter, additional, Engelhardt, Monika, additional, Jenner, Matthew, additional, Corso, Alessandro, additional, Dürig, Jan, additional, Pavic, Michel, additional, Salomo, Morten, additional, Beksac, Meral, additional, Oriol, Albert, additional, Lindsay, Jindriska, additional, Liberati, Anna Marina, additional, Galli, Monica, additional, Robak, Pawel, additional, Larocca, Alessandra, additional, Yagci, Munci, additional, Vural, Filiz, additional, Kanate, Abraham S., additional, Jiang, Ruiyun, additional, Grote, Lara, additional, Peluso, Teresa, additional, and Dimopoulos, Meletios, additional

Published
2021
Full Text
View/download PDF

3. Retrospective study of treatment patterns and outcomes post‐lenalidomide for multiple myeloma in Canada

Author

Reece, Donna E., primary, Masih‐Khan, Esther, additional, Atenafu, Ehetu G., additional, Jimenez‐Zepeda, Victor H., additional, McCurdy, Arleigh, additional, Song, Kevin, additional, LeBlanc, Richard, additional, Sebag, Michael, additional, White, Darrell, additional, Cherniawsky, Hannah, additional, Reiman, Anthony, additional, Stakiw, Julie, additional, Louzada, Martha L., additional, Kotb, Rami, additional, Aslam, Muhammad, additional, Gul, Engin, additional, and Venner, Christopher P., additional

Published
2021
Full Text
View/download PDF

4. The impact of lenalidomide maintenance on second‐line chemotherapy in transplant eligible patients with multiple myeloma

Author

Cherniawsky, Hannah M., primary, Kukreti, Vishal, additional, Reece, Donna, additional, Masih‐Khan, Esther, additional, McCurdy, Arleigh, additional, Jimenez‐Zepeda, Victor H., additional, Sebag, Michael, additional, Song, Kevin, additional, White, Darrell, additional, Stakiw, Julie, additional, LeBlanc, Richard, additional, Reiman, Anthony, additional, Louzada, Martha, additional, Aslam, Muhammad, additional, Kotb, Rami, additional, Gul, Engin, additional, Atenafu, Eshetu, additional, and Venner, Christopher P., additional

Published
2021
Full Text
View/download PDF

5. Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.

Author

Richardson, Paul G., Schjesvold, Fredrik, Weisel, Katja, Moreau, Philippe, Anderson, Larry D., White, Darrell, Rodriguez‐Otero, Paula, Sonneveld, Pieter, Engelhardt, Monika, Jenner, Matthew, Corso, Alessandro, Dürig, Jan, Pavic, Michel, Salomo, Morten, Beksac, Meral, Oriol, Albert, Lindsay, Jindriska, Liberati, Anna Marina, Galli, Monica, and Robak, Pawel

Subjects
MULTIPLE myeloma, BORTEZOMIB, PROGNOSIS, DEXAMETHASONE, PROGRESSION-free survival
Abstract

Objective: We evaluated the efficacy and safety of pomalidomide, bortezomib, and dexamethasone (PVd) vs bortezomib and dexamethasone (Vd) by age, renal function, and high‐risk cytogenetic abnormalities in lenalidomide‐pretreated patients with multiple myeloma at first relapse. Methods: OPTIMISMM was a phase 3, multicenter, open‐label, randomized study (NCT01734928; N = 559). The primary endpoint was progression‐free survival (PFS). Results: Overall, 226 patients had received one prior line of therapy. PVd significantly prolonged PFS vs Vd in patients aged ≤65 years (median, 22.0 vs 13.1 months; P =.0258) and >65 years (median, 17.6 vs 9.9 months; P =.0369). Median PFS in patients with renal impairment (RI; creatinine clearance <60 mL/min) was 15.1 months with PVd vs 9.5 months with Vd (hazard ratio [HR], 0.67 [95% CI, 0.34‐1.34]). In patients without RI, median PFS was 22.0 vs 13.1 months (HR, 0.45 [95% CI, 0.27‐0.76]). In patients with high‐risk cytogenetics, median PFS was 14.7 vs 9.9 months (HR, 0.39 [95% CI, 0.13‐1.17]). PVd significantly improved overall response rate vs Vd in all subgroups. The safety profile of PVd was consistent with previous reports. Conclusions: These findings confirmed the benefits of PVd at first relapse, including in patients with poor prognostic factors. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results